DOI 10.1021/acs.jmedchem.5c02693
TIM-3 Inhibitor Development: Overcoming Immune Evasion in Cancer Therapy.
Аннотация
Although immune checkpoint blockade therapies targeting PD-1/PD-L1 and CTLA-4 have achieved remarkable clinical success, limitations such as low response rates and acquired resistance remain significant challenges. TIM-3 has recently emerged as a key immunosuppressive receptor and a promising therapeutic target for augmenting antitumor immunity. However, the development of TIM-3 inhibitors is highly imbalanced: multiple antibody-based candidates have entered Phase III trials, whereas small-molecule inhibitors are still in the preclinical stage, with current research remaining fragmented and lacking systematic structure-activity relationship studies. This Account systematically summarizes the structural and functional mechanisms of TIM-3, with a focus on recent advances in the discovery and development of small-molecule TIM-3 inhibitors. We highlight representative lead compounds identified through virtual screening and rational design and discuss future directions to facilitate the development of novel TIM-3-targeted agents.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.